Trevi Therapeutics (TRVI) Amortization of Deferred Charges (2018 - 2023)
Trevi Therapeutics' quarterly Amortization of Deferred Charges came in at $99000.0 in Q2 2023, down 30.77% year-on-year from $143000.0 in Q2 2022, and up 22.22% quarter-over-quarter from $81000.0 in Q1 2023.
Trevi Therapeutics has reported Amortization of Deferred Charges for 5 years, with the latest figure at $99000.0 in Q2 2023.
- For the quarter ending Q2 2023, Amortization of Deferred Charges fell 30.77% year-over-year to $99000.0; the trailing twelve-month figure through Dec 2023 stood at $180000.0 (down 65.38% YoY), and the FY2023 full-year result was $180000.0, down 65.38% from the prior year.
- Amortization of Deferred Charges for Q2 2023 stood at $99000.0, up from $81000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $159000.0 in Q4 2020, with the low at $81000.0 in Q1 2023.
- Average Amortization of Deferred Charges over 4 years is $132545.5, with a median of $145000.0 recorded in 2021.
- Year-over-year, Amortization of Deferred Charges grew 6.21% in 2022 and plunged 47.4% in 2023.
- Tracing TRVI's Amortization of Deferred Charges over 4 years: stood at $159000.0 in 2020, then retreated by 1.26% to $157000.0 in 2021, then sank by 35.67% to $101000.0 in 2022, then declined by 1.98% to $99000.0 in 2023.
- The last three Amortization of Deferred Charges figures came in at $99000.0 (Q2 2023), $81000.0 (Q1 2023), and $101000.0 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 99,000.00 |
| Jun 30, 2023 | 99,000.00 |
| Mar 31, 2023 | 81,000.00 |
| Mar 31, 2023 | 81,000.00 |
| Dec 31, 2022 | 101,000.00 |
| Dec 31, 2022 | 101,000.00 |
| Sep 30, 2022 | 122,000.00 |
| Sep 30, 2022 | 122,000.00 |
| Jun 30, 2022 | 143,000.00 |
| Jun 30, 2022 | 143,000.00 |
| Mar 31, 2022 | 154,000.00 |
| Mar 31, 2022 | 154,000.00 |
| Dec 31, 2021 | 157,000.00 |
| Dec 31, 2021 | 157,000.00 |
| Sep 30, 2021 | 151,000.00 |
| Sep 30, 2021 | 151,000.00 |
| Jun 30, 2021 | 146,000.00 |
| Jun 30, 2021 | 146,000.00 |
| Mar 31, 2021 | 145,000.00 |
| Mar 31, 2021 | 145,000.00 |
| Dec 31, 2020 | 159,000.00 |
| Dec 31, 2020 | 159,000.00 |
| Jun 30, 2018 | 17,000.00 |
| Jun 30, 2018 | 17,000.00 |
| Mar 31, 2018 | 43,000.00 |
| Mar 31, 2018 | 43,000.00 |